Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?

Hugo C. Turner*, Wilma A. Stolk, Anthony W. Solomon, Jonathan D. King, Antonio Montresor, David H. Molyneux, Jaspreet Toor

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

7 Citations (Scopus)

Abstract

Neglected tropical diseases (NTDs) remain a significant cause of morbidity and mortality in many low-income and middle-income countries. Several NTDs, namely lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases (STH) and trachoma, are predominantly controlled by preventive chemotherapy (or mass drug administration), following recommendations set by the WHO. Over one billion people are now treated for NTDs with this strategy per year. However, further investment and increased domestic healthcare spending are urgently needed to continue these programmes. Consequently, it is vital that the cost-effectiveness of preventive chemotherapy is understood. We analyse the current estimates on the cost per disability-adjusted life year (DALY) of the preventive chemotherapy strategies predominantly used for these diseases and identify key evidence gaps that require further research. Overall, the reported estimates show that preventive chemotherapy is generally cost-effective, supporting WHO recommendations. More specifically, the cost per DALY averted estimates relating to community-wide preventive chemotherapy for lymphatic filariasis and onchocerciasis were particularly favourable when compared with other public health interventions. Cost per DALY averted estimates of school-based preventive chemotherapy for schistosomiasis and STH were also generally favourable but more variable. Notably, the broader socioeconomic benefits are likely not being fully captured by the DALYs averted metric. No estimates of cost per DALY averted relating to community-wide mass antibiotic treatment for trachoma were found, highlighting the need for further research. These findings are important for informing global health policy and support the need for continuing NTD control and elimination efforts.

Original languageEnglish
Article numbere005456
JournalBMJ Global Health
Volume6
Issue number8
DOIs
Publication statusPublished - 12 Aug 2021

Bibliographical note

Funding Information:
Funding HCT was supported by the Wellcome Trust core grant (106680/Z/14/Z). HCT and JT acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. JT and WAS gratefully acknowledge funding of the NTD Modelling Consortium by the Bill & Melinda Gates Foundation [OPP1184344].

Publisher Copyright:
© 2021 BMJ Publishing Group. All rights reserved.

Fingerprint

Dive into the research topics of 'Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?'. Together they form a unique fingerprint.

Cite this